Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Inflamm Res. 2014 May 30;63(9):703–710. doi: 10.1007/s00011-014-0743-3

Figure 2. TLR2 and TLR4 are required for ICAM-1 and MCP-1 production induced by biglycan.

Figure 2

A. Representative immunoblots and densitometric data show that neutralization of TLR2 markedly reduced cellular levels of ICAM-1 and MCP-1 release following treatment with biglycan (BGN, 0.10 μg/mL for 48 h), while neutralization of TLR4 had a moderate effect. B. Treatment with specific siRNAs reduced cellular TLR2 and TLR4 levels. Silencing TLR2 markedly reduced cellular ICAM-1 levels and MCP-1 release after biglycan stimulation, while silencing TLR4 had a moderate effect. Values are means ± SE. n = 3; *P<0.05, vs. untreated control; #P<0.05 vs. BGN alone; †P<0.05 vs. BGN + non-immune IgG; ‡P<0.05 vs. BGN + scrambled siRNA.